About Immunoglobulin heavy constant gamma 1
Immunoglobulin heavy constant gamma 1 (IGHG1) is a protein
from Homo sapiens identified by UniProt accession
P01857, 399 residues long.
MolForge cross-references it against 0 known binders and
201 disease associations.
Target properties
| Protein name | Immunoglobulin heavy constant gamma 1 |
| UniProt accession | P01857 |
| Gene | IGHG1 |
| Organism | Homo sapiens |
| Length | 399 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | LOW |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (201)
Diseases linked to this target (Open Targets).
- cutaneous Leishmaniasis · score 0.59
- multiple myeloma · score 0.39
- Systemic lupus erythematosus · score 0.37
- systemic lupus erythematosus · score 0.37
- immune deficiency, familial variable · score 0.08
- common variable immunodeficiency · score 0.08
- combined immunodeficiency with skin granulomas · score 0.07
- hyper-IgM syndrome type 3 · score 0.07
- classic Hodgkin lymphoma · score 0.07
- Hodgkins lymphoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P01857-F1 | alphafold | PREDICTED | 86.70 | — |
Amino-acid sequence (399 residues)
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPEL QLEESCAEAQ DGELDGLWTT ITIFITLFLL SVCYSATVTF FKVKWIFSSV VDLKQTIIPD YRNMIGQGA
Explore Immunoglobulin heavy constant gamma 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets